Villere ST Denis J & Co. LLC Lowers Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Villere ST Denis J & Co. LLC trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,886 shares of the company's stock after selling 2,125 shares during the period. IDEXX Laboratories makes up approximately 2.5% of Villere ST Denis J & Co. LLC's holdings, making the stock its 20th biggest holding. Villere ST Denis J & Co. LLC owned approximately 0.07% of IDEXX Laboratories worth $30,761,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Crewe Advisors LLC bought a new position in IDEXX Laboratories during the first quarter valued at $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC purchased a new position in IDEXX Laboratories in the second quarter worth about $28,000. E Fund Management Hong Kong Co. Ltd. increased its stake in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after acquiring an additional 57 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after purchasing an additional 60 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Up 0.1 %

IDXX traded up $0.28 on Friday, reaching $433.28. 655,728 shares of the company traded hands, compared to its average volume of 769,371. The company has a market cap of $35.48 billion, a P/E ratio of 41.78, a price-to-earnings-growth ratio of 3.70 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a one year low of $404.74 and a one year high of $583.39. The firm has a fifty day simple moving average of $472.83 and a two-hundred day simple moving average of $485.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the previous year, the firm posted $2.53 earnings per share. The company's revenue was up 6.6% on a year-over-year basis. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on IDXX shares. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research note on Thursday, October 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a "buy" rating and a $580.00 target price on the stock. Barclays dropped their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Finally, Piper Sandler reiterated a "neutral" rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.